Viela Bio Inc. has earned a breakthrough therapy designation from the Food and Drug Administration for a product to treat neuromyelitis optica spectrum disorder, a life-threatening autoimmune disease that impacts the central nervous system. The FDA granted breakthrough status to the company’s candidate, inebilizumab, following positive results from a pivotal study that was “the largest monotherapy study ever conducted in NMOSD,” said Dr. Jorn Drappa, chief medical officer and head of research…
from https://www.bizjournals.com/baltimore/news/2019/04/19/medimmune-spinoff-scores-breakthrough-status-for.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/184295786627
No comments:
Post a Comment